Non-Alcoholic Steatohepatitis-Related Cirrhosis
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
This activity is supported by an educational grant from Novo Nordisk.
Intercept pivots away from NASH following second FDA rejection for obeticholic acid
The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.
FDA grants fast track designation to Merck’s efinopegdutide for treatment of NASH
The FDA granted fast track designation to efinopegdutide for the treatment of nonalcoholic steatohepatitis, according to a manufacturer’s press release.
Intercept ‘disappointed’ after FDA setback for top NASH contender; stock drops 16%
Intercept Pharmaceuticals saw a 16% drop in its stock value after an FDA advisory committee declined to approve obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis.
NAFLD ‘not fit for purpose’: Experts debate impact of changing name vs. definition
WASHINGTON — The term ‘non-alcoholic fatty liver disease’ no longer reflects current knowledge of the disease and should be changed, members of the NAFLD Nomenclature steering committee noted during The Liver Meeting.
Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo
WASHINGTON — Efruxifermin improved liver histology, liver fat content and noninvasive markers of disease in patients with stage 2 or 3 fibrosis related to nonalcoholic steatohepatitis, according to late-breaking data at The Liver Meeting.
Non-liver-related mortality can be higher in NAFLD ‘depending on age, fibrosis stage’
A patient outcomes simulator found that non-liver-related mortality could surpass liver-related mortality in patients with nonalcoholic fatty liver disease, depending on age and fibrosis stage at diagnosis, noted data in JAMA Network Open.
FDA grants fast track status to ervogastat plus clesacostat for NASH
Fatigue in patients with advanced NASH may increase risk for adverse events
Worse fatigue at baseline among patients with nonalcohol steatohepatitis-related advanced fibrosis and cirrhosis correlated with a higher risk adverse clinical events, according to published results.